Phase 1, randomized, placebo controlled, double blind, single dose-escalation study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous IQNLF in healthy subjects.

The test compound is a drug that is being developed for the treatment of
anthrax.

To investigate the safety and tolerability of the intravenously applied
(directly given into a blood vessel) new test compound.

Phase 1, randomized, placebo controlled, double blind, single dose-escalation
study.

36 healthy male and female volunteers will participate in the trial. 32 men and
women will receive an infusion once of 0.5, 1, 2.5 or 7.5 test compound per
kilo body weight or placebo.

The test medication has not been previously tested in humans but was
extensively tested in animals. In these animal models multiple dosing were
given and no side effects were seen. However unknown side effects or allergic
reactions can never be excluded.

The dose levels are selected on the basis of research results in animals and
humans. The risk to health at these dose levels is limited but you may
experience one of the above mentioned side-effects or other symptoms not
previously reported. Your health will be closely monitored during the trial to
minimize these risks.